Performance evaluation of Panther Fusion SARS-CoV-2 assay for detection of SARS-CoV-2 from deep throat saliva, nasopharyngeal, and lower-respiratory-tract specimens
Detection Principle
NucleicAcid-PCR based
Target
not specified
Testing Method Category
PCR_KIT
Testing Method
kit
Testing Method - Additional Info
performance evaluation of the Panther Fusion severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2) assay (PF assay) (Hologic, Inc.) in comparison to the TIB?Molbiol LightMix SarbecoV E?gene assay (TIB?Molbiol assay) (TIB?Molbiol) using deep throat saliva (DTS), nasopharyngeal (NP) and lower respiratory tract (LRT) specimens.
Reported Performance
PPA: 96.43% (NP), 100% (LRT), 96% (DTS), 97.53% (overall); NPA: 100% (NP), 100% (LRT), 100% (DTS), 100% (overall)
Sample Size
158 samples (142 patients)
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements